{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:21:12Z","timestamp":1761920472392,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000406","name":"Motor Neurone Disease Association","doi-asserted-by":"publisher","award":["2016\/17"],"award-info":[{"award-number":["2016\/17"]}],"id":[{"id":"10.13039\/501100000406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.msard.2018.05.010","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T05:10:34Z","timestamp":1527829834000},"page":"20-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine"],"prefix":"10.1016","volume":"24","author":[{"given":"O.","family":"Yildiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-0579","authenticated-orcid":false,"given":"N.","family":"Dubuisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1207-8625","authenticated-orcid":false,"given":"K.","family":"Allen-Philbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"G.","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-8711","authenticated-orcid":false,"given":"D.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gnanapavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-8893","authenticated-orcid":false,"given":"K.","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.05.010_bib0001","article-title":"Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis","author":"Afolabi","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2018.05.010_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.410","article-title":"Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis","author":"Alvarez-Gonzalez","year":"2017","journal-title":"Ann. Clin. Trans. Neurol"},{"key":"10.1016\/j.msard.2018.05.010_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2016-315106.121","article-title":"Treating multiple sclerosis with cladribine","volume":"87","author":"Alvarez-Gonzalez","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.05.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2018.05.010_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2018.05.010_bib0056","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1212\/NXI.0000000000000271","article-title":"Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS","volume":"3","author":"Bergman","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2018.05.010_bib0006","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000026245","article-title":"The cladribine trial in secondary progressive multiple sclerosis: a reanalysis","volume":"19","author":"Beutler","year":"2000","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.msard.2018.05.010_bib0007","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1073\/pnas.93.4.1716","article-title":"The treatment of chronic progressive multiple sclerosis with cladribine","volume":"93","author":"Beutler","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.msard.2018.05.010_bib0008","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B","article-title":"Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients","volume":"48","author":"Bjartmar","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2018.05.010_bib0009","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ane.12239","article-title":"Assessing tissue damage in multiple sclerosis: a biomarker approach","volume":"130","author":"Burman","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2018.05.010_bib0010","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1212\/WNL.0000000000002745","article-title":"Malignancies after mitoxantrone for multiple sclerosis: a retrospective cohort study","volume":"86","author":"Buttmann","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.05.010_bib0011","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.05.010_bib0012","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.05.010_bib0013","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.05.010_bib0014","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.05.010_bib0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ene.12307","article-title":"Change practice now! Using atraumatic needles to prevent post lumbar puncture headache","volume":"21","author":"Davis","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2018.05.010_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/1352458517717811","article-title":"Disease modification in advanced MS: Focus on upper limb function","author":"Dubuisson","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.05.010_bib0017","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/1352458517709362","article-title":"Science is 1% inspiration and 99% biomarkers","volume":"23","author":"Dubuisson","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.05.010_bib0018","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/brain\/120.3.393","article-title":"Axonal damage in acute multiple sclerosis lesions","volume":"120 (Pt 3)","author":"Ferguson","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.msard.2018.05.010_bib0019","doi-asserted-by":"crossref","first-page":"559","DOI":"10.33588\/rn.6212.2016196","article-title":"Review of the novelties from the 31st ECTRIMS congress, 2015, presented at the 8th post-ECTRIMS meeting","volume":"62","author":"Fernandez","year":"2016","journal-title":"Rev. Neurol."},{"issue":"Suppl3","key":"10.1016\/j.msard.2018.05.010_bib0020","first-page":"658","article-title":"Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study","volume":"23","author":"Fox","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2018.05.010_bib0021","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.05.010_bib0022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.05.010_bib0023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.msard.2017.01.007","article-title":"Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses","volume":"12","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2018.05.010_bib0024","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.05.010_bib0025","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.05.010_bib0026","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH","volume":"308","author":"Hauser","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.05.010_bib0027","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2018.05.010_bib0028","series-title":"Cerebrospinal Fluid in Clinical Neurology","first-page":"407","article-title":"Guidelines on cerebrospinal fluid analysis","author":"Hegen","year":"2015"},{"key":"10.1016\/j.msard.2018.05.010_bib0029","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.msard.2018.05.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.05.010_bib0031","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0000000000001491","article-title":"Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis","volume":"84","author":"Kuhle","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.05.010_bib0032","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1111\/ane.12151","article-title":"Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis","volume":"128","author":"Kuhle","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2018.05.010_bib0033","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.05.010_bib0034","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Oral Cladribine for early MS (ORACLE MS) study group. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.05.010_bib0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2018.05.010_bib0036","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain"},{"issue":"Suppl 1","key":"10.1016\/j.msard.2018.05.010_bib0037","first-page":"471a","article-title":"On the pharmacokinetics of 2-chloro-2-deoxyadenosine (CdA) in cerebrospinal fluid (CSF)","volume":"80","author":"Lillemark","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.msard.2018.05.010_bib0038","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.05.010_bib0039","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2018.05.010_bib0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/jnnp-2013-305450","article-title":"Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the general practice research database","volume":"85","author":"Mackenzie","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.05.010_bib0041","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.msard.2018.05.010_bib0042","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1212\/01.WNL.0000098880.19793.B6","article-title":"Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS","volume":"61","author":"Malmestr\u00f6m","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.05.010_bib0043","doi-asserted-by":"crossref","first-page":"A47","DOI":"10.1136\/jnnp-2017-ABN.164","article-title":"PO134 personalised dosing of cladribine to treat multiple sclerosis","volume":"88","author":"Mao","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.05.010_bib0044","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.05.010_bib0045","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.nurt.2007.08.003","article-title":"Immunosuppressive agents in multiple sclerosis","volume":"4","author":"Neuhaus","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2018.05.010_bib0046","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0006-8993(03)03219-0","article-title":"Elevated neurofilament levels in neurological diseases","volume":"987","author":"Norgren","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.msard.2018.05.010_bib0047","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","article-title":"Neurofilament and glial fibrillary acidic protein in multiple sclerosis","volume":"63","author":"Norgren","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.05.010_bib0048","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","article-title":"No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine","volume":"2","author":"Pakpoor","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"year":"2016","series-title":"A Textbook of Neuroanatomy","author":"Patestas","key":"10.1016\/j.msard.2018.05.010_bib0049"},{"key":"10.1016\/j.msard.2018.05.010_bib0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss","volume":"233","author":"Petzold","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2018.05.010_bib0051","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","article-title":"Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial","volume":"54","author":"Rice","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.05.010_bib0057","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1212\/WNL.52.5.1090","article-title":"Neurofilament protein levels in CSF are increased in dementia","volume":"52","author":"Rosengren","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.05.010_bib0052","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.05.010_bib0053","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.05.010_bib0054","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1007\/s00415-014-7507-4","article-title":"N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis","volume":"261","author":"Trentini","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.05.010_bib0055","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/archneurol.2011.241","article-title":"Interferon beta-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up","volume":"68","author":"Tur","year":"2011","journal-title":"Arch. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:40:57Z","timestamp":1761900057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818301500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":57,"alternative-id":["S2211034818301500"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.05.010","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}